Analyst Warns FDA May Not Approve Neurochem's Drug

An analyst warned that Neurochem Inc.'s (NRMX) Alzheimer's disease drug will probably fail a Phase III clinical trial and that the FDA is not likely to approve the company's Amyloid A Amyloidosis medication. The stock price dropped $1.07 to close at $6.42.